DM
SPRY icon

Diker Management’s ARS Pharmaceuticals SPRY Stock Holding History

Diker Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$525K Buy
65,508
+32,000
+95% +$275K 0.4% 30
2026
Q1 		$269K Hold
33,508
– – 0.24% 38
2025
Q4 		$390K Sell
33,508
-10,000
-23% -$97.3K 0.3% 37
2025
Q3 		$437K Buy
43,508
+2,508
+6% +$36K 0.35% 30
2025
Q2 		$715K Buy
41,000
+20,000
+95% +$289K 0.67% 22
2025
Q1 		$264K Buy
+21,000
New +$253K 0.32% 29

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Diker Management's SPRY Position: Q2 2026 in Review

Diker Management increased its ARS Pharmaceuticals (SPRY) stake by 95% in Q2 2026, buying an estimated $275K and bringing the position to 65,508 shares worth $525K. The position accounts for 0.4% of the portfolio, ranked #30.

Diker Management first reported a position in SPRY in Q1 2025 and has held it in 6 quarters since. The position peaked at $715K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Diker Management held 65,508 shares of ARS Pharmaceuticals worth $525K as of Q2 2026.
  • Diker Management bought 32,000 ARS Pharmaceuticals shares in Q2 2026, an estimated $275K.
  • ARS Pharmaceuticals made up 0.4% of Diker Management's portfolio in Q2 2026, its #30 holding.
  • Diker Management first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Diker Management's ARS Pharmaceuticals position peaked at $715K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Diker Management's 13F filing for Q2 2026, filed 14 Aug 2026.